|
Indian CDMOs dominate in complex nutraceutical formulations with benchmark for innovation & reliability
|
|
Nandita Vijayasimha, Bengaluru
August 04 , 2025
|
|
|
India's contract development and manufacturing organizations (CDMOs) are emerging as global leaders in delivering high-precision, customized nutraceutical formulations. The companies have advanced R&D capabilities, scalable infrastructure, that demand technical complexity, ingredient synergy, and speed to market. As global demand for personalised and functional health products grows, Indian CDMOs are setting a new benchmark for efficiency, innovation, and reliability in the nutraceuticals.
Suresh Garg, CMD and founder, Zeon Lifesciences, said that CDMOs, which were once viewed merely as manufacturers, now serve as full-spectrum innovation partners in the nutraceutical and wellness space. Their role has expanded to include research, formulation, regulatory assistance, clinical validation, and international distribution. This shift enables emerging brands to meet evolving consumer preferences like personalised supplements and travel-friendly formats. With in-house expertise, CDMOs help clients fast-track product development while maintaining compliance with global standards. By facilitating cross-border collaboration, they assist brands in navigating complex regulations and unlocking global market access.
CDMOs are now shaping a more actively-evolving, consumer-friendly industry that can match pace with the fast-changing health and wellness trends throughout the geography. They are reshaping the nutrition and Ayurveda landscape by combining ancient wisdom with advanced science, he added.
By investing in research, clinical studies, and scientific collaborations, CDMOs are developing differentiated brands. In fact, they extend advanced testing and validation capabilities, increasing product safety and consumer trust. Innovations like nanotechnology and bio-enhanced formats are extending the limits of product effectiveness. Such an input is crucial in adapting ancient healing traditions to meet modern health demands while retaining credibility in competitive, regulation-driven markets, Garg told Pharmabiz in an email.
The organisations enable a streamlined process by bringing early-stage ideation formulation, pilot trials, scaling, and packaging into a cohesive workflow. This all-in-one approach often shortens development time and reduces the typical back-and-forth between departments or vendors. With skilled teams and tried-and-tested systems, they take much of the pressure off internal teams and help brands get to market more swiftly. Real-time project updates are provided to track progress, he said.
For small and medium nutraceutical enterprises, scaling production can pose a financial and logistical challenge. CDMOs with their flexible infrastructure allow firms to increase or reduce production volumes without bigger capital expenses.
By consolidating procurement and production, CDMOs achieve economies-of-scale by lowering per-unit costs. Their expertise in process optimisation helps minimise delays and reduction of waste, which is vital for lean operations. Managing complex regulatory tasks and logistics, they maximise human resource deployment to focus on building market presence. Such agility allows to swiftly respond to shifting consumer needs and compliance changes, allowing them to be sustainable and competitive, he noted.
With personalised wellness options and demand for niche wellness solutions, CDMOs are stepping up to create brands with small-batch production ideal for specialised diets and clinical use. Implementing digital tools and real-time data help speed up both formulation development and testing. This helps to companies to scale-up production of novel products, he said.
In sync with today's climate-conscious world, Indian CDMOs are staying agile and responsive to environmental and regulatory shifts. With adequate technical expertise, Indian CDMOs now dominate the complex nutraceutical formulation space for personalised nutrition setting new benchmarks for reliability, customisation, and sustainability.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|